Menu

Theranos Goes Under

The discredited blood-testing company announced its decision to close in a company-wide email.

Sep 5, 2018
Sukanya Charuchandra
Elizabeth Holmes

The blood-testing company Theranos will be dissolving and returning its remaining cash (approximately $5 million) to its creditors, reports The Wall Street Journal

The troubled company’s CEO and general counsel, David Taylor, made the declaration in an email to shareholders and said, “I write with difficult news about the future of the Company.” The firm’s remaining employees worked their last day on August 31. 

The move comes after Theranos failed to secure a buyer or further investments and ended up breaking the terms of its $65 million loan from Fortress Investment Group. By brokering of a deal with the investment firm, Theranos gets to consolidate its leftover money in a trust for creditors that might take between six to 12 months to process. The email states, “Because the Company’s cash is not nearly sufficient to pay all of its creditors in full, there will be no distributions to shareholders.” 

Three months ago, Theranos’s founder Elizabeth Holmes and former CEO Ramesh Balwani faced criminal charges for committing a multimillion-dollar fraud against investors, doctors, and patients. According to Financial Times, Holmes resigned immediately following the indictment. Among the company’s most well-known investors were Rupert Murdoch, Walmart’s Walton family, and the family of Betsy DeVos.

The criminal charges are in addition to the Securities and Exchange Commission’s civil charges against Theranos, Holmes, and Balwani for defrauding investors of $700 million, a case that Balwani is still fighting. 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.